Abstract
Background Most of the population has been infected with SARS-CoV-2 and, thus, is primed by natural exposure. As such, it was assessed whether a single dose of the monovalent XBB.1.5 vaccine, NVX-CoV2601, elicited a comparable immune response to XBB.1.5 in seropositive unvaccinated participants to that in previously vaccinated participants, thereby allowing the former to forego a two-dose primary series. Methods In this phase 2/3, open-label, single-arm study (2019nCoV-313/NCT05975060 [part 2]), vaccine-naive participants ≥18 years with previous SARS-CoV-2 infection received one dose of NVX-CoV2601. This analysis compared the 28-day immunogenicity and safety of NVX-CoV2601 in vaccine-naive and previously vaccinated (≥3 prior mRNA-based vaccines, from 2019nCoV-313 part 1) participants. Noninferiority of neutralizing antibody (nAb) response in vaccine-naive versus vaccinated participants was the primary objective. The day-28 geometric mean titer (GMT) ratio (GMTR) and seroresponse rate (SRR; percentage of participants with a ≥4-fold rise in antibody response from baseline) were measured, and safety was assessed. Results Of the participants enrolled from September 11–November 15, 2023, per-protocol sets included 306/338 (90.5%) vaccine-naive and 309/332 (93.1%) vaccinated participants. At day 28, adjusted GMTs (95% CI) against XBB.1.5 in the vaccine-naive and vaccinated groups were 1491.5 (1277.5–1741.4) and 841.4 (723.9–978.0), respectively. The vaccine-naive–vaccinated nAb GMTR was 1.8 (95% CI 1.43–2.20) and SRRs were 74.3% and 64.3% for vaccine-naive and vaccinated participants, respectively (SRR difference: 10.0 [95% CI 2.6–17.4]). No new safety signals or events of special interest were reported. Conclusions A single dose of NVX-CoV2601 in vaccine-naive participants with a history of SARS-CoV-2 infection elicited a robust neutralizing antibody response that was noninferior to that observed in vaccinated participants. The vaccine was well-tolerated. These data support the use of NVX-CoV2601 as a single dose, regardless of prior vaccination history. Trial registration: NCT05975060
Competing Interest Statement
Katia Alves reports a relationship with Novavax Inc that includes: employment and equity or stocks. Alex Kouassi reports a relationship with Novavax Inc that includes: employment and equity or stocks. Joyce S. Plested reports a relationship with Novavax Inc that includes: employment and equity or stocks. Raj Kalkeri reports a relationship with Novavax Inc that includes: employment and equity or stocks. Katherine Smith reports a relationship with Novavax Inc that includes: employment and equity or stocks. Muneer Kaba reports a relationship with Novavax Inc that includes: employment and equity or stocks. Joy Nelson reports a relationship with Novavax Inc that includes: employment and equity or stocks. Mingzhu Zhu reports a relationship with Novavax Inc that includes: employment and equity or stocks. Shane Cloney-Clark reports a relationship with Novavax Inc that includes: employment and equity or stocks. Zhaohui Cai reports a relationship with Novavax Inc that includes: employment and equity or stocks. Raburn M. Mallory reports a relationship with Novavax Inc that includes: employment and equity or stocks. Fernando Noriega reports a relationship with Novavax Inc that includes: employment and equity or stocks. This study was funded by Novavax, Inc. The authors received medical writing and editorial support funded by the study sponsor. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Clinical Trial
NCT05975060
Funding Statement
Novavax, Inc. funded the 2019nCoV-313 study and provided the vaccine. Novavax, Inc. collaborated with the investigators on the protocol, data analysis and interpretation, and preparation of this paper.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by Advarra, Inc. (Columbia, MD, USA), and the study was conducted according to the principles of the International Conference on Harmonization Good Clinical Practice Guideline, adopting the principles of the Declaration of Helsinki, as well as all applicable national, state, and local laws and regulations. All participants provided written informed consent
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Study information is available online at https://www.clinicaltrials.gov/study/NCT05975060. Requests submitted to the corresponding author will be considered upon publication of this article.
